If you’re planning to be at this year’s 67th American Society of Tropical Medicine and Health Annual Meeting in New Orleans, then do come and see us. We’ll be sharing our latest results and tools at Booth 416 – so do stop by to meet the IDDO team to exchange ideas on how we might work together.

The latest results are now live on three WWARN surveyors:

ASTMH is upon us – we look forward to seeing many of our partners in the USA very soon.

Over 200 delegates traveled from more than 50 countries to attend the first ever conference on Medicine Quality and Public Health (MQPH) in Oxford from 23-28 September 2018.

Researchers from WWARN and the Infectious Diseases Data Observatory (IDDO) presented at the 9th European and Developing Countries Clinical Trials Partnership (EDCTP) forum held in Lisbon, Portugal from 17-21 September 2018.

The Infectious Diseases Data Observatory (IDDO), together with WWARN and many partners including the United States Pharmacopeia (USP), the Concept Foundation, the Mahidol Oxford Tropical Medicine Research Unit (MORU) and the Wellcome Trust are hosting the first Medicine Quality and Public Health con...

The Infectious Diseases Data Observatory (IDDO), together with many partners including the United States Pharmacopeia (USP), the Concept Foundation, the Mahidol Oxford Tropical Medicine Research Unit (MORU) and the Wellcome Trust will host the first Medicine Quality and Public Health conference at K...

We are delighted to attend the 9th EDCTP Forum in Lisbon, Portugal this week.

We are delighted to attend the 9th EDCTP Forum in Lisbon, Portugal this week.

Bangkok / Oxford, 22 August 2018 – The economic costs of antimicrobial resistance (AMR) for every course of antibiotics are considerable, and much higher than their purchase cost, say researchers.

The 2018 Global Health Journalism Fellowship will invite outstanding young journalists to participate in the first ever international conference on Medicine Quality and Public Health at the University of Oxford. Application deadline is 12 August 2018

The UK’s Department for International Development (DFID) recently announced that it will commit £9.2 million (USD 13.15 million) of funding to support a new malaria research programme lead by the Mahidol-Oxford Research Unit (MORU). The programme entitled ‘Development of Triple Artemisinin Combinati...

Have you heard of the Malaria Clinical Trials Toolkit? The ‘toolkit’ aims to improve the quality and standard of trial data by creating a step-by-step guide for researchers and clinicians on how to design, implement and analyse malaria clinical trials.

GSK and Medicines for Malaria Venture (MMV) announce FDA approval of single-dose treatment Krintafel (tafenoquine) to prevent the relapse of P. vivax malaria.

WWARN's Clinical Group has published results supporting the need for a radical cure strategy to tackle one of the most debilitating forms of malaria caused by the Plasmodium vivax parasite.

The WWARN network is very saddened by the news of the passing of Prof Ogobara Doumbo on Saturday 9 June in Marseille, France. Prof Doumbo was a long-standing WWARN partner and highly respected for his contribution to the malaria community through co-founding the Centre for Malaria Research & Trainin...

WWARN’s Clinical Group led by Professor Ric Price joined government ministers, international institutes, malaria experts and civil society organisations in Melbourne Australia for the First Malaria World Congress 1-5 July 2018. Discussions focussed on elimination efforts, cross-sectoral collaboratio...

Current recommended treatment regimens for the most widely used medicine for uncomplicated Plasmodium falciparum malaria may be sub-optimal for small children and pregnant women according to a study led by Prof. Joel Tarning, Head of Pharmacometrics at the WorldWide Antimalarial Resistance Network (...

A pioneering conference will bring leading professionals from all over the world to Oxford, UK to discuss strategies for tackling poor quality medical products on a global scale.

The World Health Organization (WHO) recommended in 2012 to add single low-dose primaquine (SLDPQ) to standard artemisinin based combination treatments (ACTs) to block the transmission of Plasmodium falciparum malaria. The target dose of 0.25 mg base/kg body weight (15 mg in a 60 kg adult) was consid...